Novartis on Monday announced that it is broadening its cancer immunotherapy research program with the acquisition of CoStim Pharmaceuticals, a Cambridge, Mass.-based, privately held biotechnology company focused on harnessing the immune system to eliminate immune-blocking signals from cancer.
A drug made by Novartis extends the lives of patients with a life-threatening blood cancer to a greater extent than conventional therapy or placebo, according to results of a late-stage clinical trial.
Alliance Boots announced that it is establishing a specialized investment fund, B&B Capital Partners, which will be focused on small- and medium-sized consumer brand businesses within the health, wellness, beauty and personal care sectors.
The Lonza Group recently launched its Alomune daily immune supplements into the U.S. market, backing the product with clinical trials that show the supplement helps improve the body’s natural defenses for optimized immune health.
Swiss Precision Diagnostics recently launched its Clearblue Advanced Pregnancy Test with Weeks Estimator — the first and only pregnancy test that also provides an estimate of time since ovulation for women testing pregnant — into the U.S. marketplace.
Royal Ahold has hired Hanneke Faber as chief commercial officer as part of a new executive committee leadership structure that the Dutch supermarket operator said would allow it to accelerate its "reshaping retail" business strategy by simplifying governance structure and decision making.
Alliance Boots on Friday announced that it has distributed its equity interest in Galenica, its Swiss associate, to the group’s ultimate parent company, AB Acquisitions Holdings, in accordance with the terms of the agreement with Walgreens reached last year.
Nestlé on Tuesday named Luis Cantarell head of Nestlé Nutrition with the departure of Kurt Schmidt, deputy EVP Nestlé Nutrition, who has decided to leave the company for personal reasons effective Dec. 1.
A Swiss subsidiary of drug maker Celgene Corp. said its chemotherapy drug produced "significant" improvement in progression-free survival in patients with a deadly skin cancer that had spread elsewhere in the body.
Progress at re-opening its manufacturing facility in Lincoln, Neb., has been slow-going, Novartis reported Thursday, but the company has contracted third-party manufacturers to resume production of Excedrin, Lamisil and Triaminic.